What is Elasmogen?
Elasmogen is a privately-held biopharmaceutical company dedicated to the development of innovative soloMER products targeting solid-tumor cancers, systemic inflammatory diseases, and inflammatory conditions of the gut. Founded in 2016 and operating within the United Kingdom's robust biologics cluster, the company leverages its proprietary technology to create novel therapeutic candidates. Its strategic focus on unmet medical needs in oncology and immunology positions it as a key player in the biopharmaceutical landscape.
How much funding has Elasmogen raised?
Elasmogen has raised a total of $13.9M across 3 funding rounds:
Unspecified
$1.5M
Private Equity
$2.6M
Other Financing Round
$9.9M
Unspecified (2017): $1.5M with participation from Deepbridge Capital and Scottish Investment Bank
Private Equity (2020): $2.6M led by Deepbridge Capital
Other Financing Round (2022): $9.9M supported by BFG International
Key Investors in Elasmogen
BFG International
BFG International, established in 1975, is a manufacturer specializing in composite materials, offering solutions across various industries including renewable energy and automotive. Their participation in Elasmogen's funding round suggests an interest in innovative material science applications within the biopharmaceutical sector.
Scottish Investment Bank
The Scottish Investment Bank, part of Scottish Enterprise, is a national economic development agency supporting businesses in Scotland. Their investment in Elasmogen highlights a commitment to fostering growth in the region's life sciences sector.
Deepbridge Capital
Deepbridge Capital is a private investor network focused on innovative Life Sciences and Technology companies, providing access to vetted EIS-qualifying opportunities for experienced investors. Their continued backing of Elasmogen signifies strong belief in the company's technological advancements and market strategy.
What's next for Elasmogen?
With the recent major strategic investment, Elasmogen is poised for accelerated development and potential commercialization of its soloMER pipeline. The substantial enterprise-level backing indicates confidence from investors in the company's scientific approach and market potential. Future endeavors will likely involve expanding clinical trials, further research and development, and potentially forging strategic partnerships to bring its innovative cancer and inflammatory disease treatments to patients. This financing round is critical for navigating the complex path from preclinical research to market approval.
See full Elasmogen company page
